TrialTargeted oncology2024

Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.

Yeokyeong Shin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.